The voxzogo market research report is one of a series of new reports that provides voxzogo market statistics, including the voxzogo industry global market size, regional shares, competitors with the voxzogo market share, detailed voxzogo market segments, market trends, and opportunities, and any further data you may need to thrive in the voxzogo industry. This voxzogo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to growing awareness and diagnosis, rising demand for effective treatments, an increase in investments in research and development, an increase in the elderly population, and increasing drug approvals and launches. Major trends in the forecast period include digital health integration, collaborations with research institutions, development of targeted therapies, advancements in biologic drug development, and innovative gene therapies.
The growing emphasis on rare diseases is expected to significantly drive the growth of the Voxzogo market in the future. Rare diseases are conditions that affect a small percentage of the population, typically fewer than 200,000 people in a country. The increased focus on rare diseases is being propelled by advancements in genetic research, the potential for innovative treatments, and heightened awareness of the unmet medical needs of individuals with these conditions. Investments in rare disease research benefit Voxzogo by promoting the development of treatments for conditions such as achondroplasia, expanding its availability and addressing the needs of underserved patient populations. For example, in February 2024, the Government of Canada allocated $20 million to enhance the health outcomes of children living with rare diseases. As a result, the growing attention and funding for rare diseases are fueling the expansion of the Voxzogo market.
The rise of personalized medicine is also expected to contribute to the growth of the Voxzogo market. Personalized medicine refers to treatments tailored to an individual’s genetic profile, lifestyle, and specific health conditions. This approach is gaining traction due to advancements in genomics and precision medicine, which allow for more targeted and effective treatments. Voxzogo aligns with the personalized medicine trend by providing a specific treatment for children with achondroplasia, addressing the unique genetic and biological characteristics of the condition. This tailored approach aims to improve the outcomes and quality of life for affected individuals. In February 2023, the Personalized Medicine Coalition (PMC) reported that 12 new personalized medicines were approved in 2022, accounting for 34% of all new drug approvals. This increase highlights the growing demand for precision treatments based on genetic and biomarker profiles, further driving the growth of the Voxzogo market.
A key trend within the Voxzogo market is the expansion of treatment indications to improve care for individuals with achondroplasia. Expanding these indications aims to provide enhanced growth and bone health benefits not just for the approved age group but also for adolescents and adults with achondroplasia, and potentially for other skeletal dysplasias. In October 2023, BioMarin Pharmaceutical Inc. received FDA approval for Voxzogo (vosoritide) to treat children under five years of age with achondroplasia, expanding its use beyond the previous approval for children aged five and older. Voxzogo, designed to promote linear growth in children with achondroplasia who still have open growth plates, is administered via subcutaneous injections. Clinical evidence suggests that the earlier the treatment starts, the greater the potential benefits for height improvement.
The key company operating in the voxzogo market is BioMarin Pharmaceutical Inc.
North America was the largest region in the voxzogo market in 2024. The regions covered in voxzogo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the voxzogo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Voxzogo (vosoritide) is a biologic drug designed to treat achondroplasia, a condition caused by a genetic mutation in the FGFR3 gene. Voxzogo works by counteracting the effects of FGFR3, promoting endochondral ossification - the process of bone growth at the growth plates - by modulating the activity of C-type natriuretic peptide (CNP), thereby supporting bone growth.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Voxzogo include growth hormone deficiency, Noonan syndrome, achondroplasia, and other conditions. Growth hormone deficiency (GHD) is a medical condition in which the pituitary gland fails to produce or secrete adequate growth hormone (GH), leading to impaired growth. Voxzogo is distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and clinics, and is used by a range of patients, including pediatrics, adults, and the geriatric population.
The voxzogo market consists of sales of injection delivery devices, supportive therapies, genetic testing kits, and growth monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to growing awareness and diagnosis, rising demand for effective treatments, an increase in investments in research and development, an increase in the elderly population, and increasing drug approvals and launches. Major trends in the forecast period include digital health integration, collaborations with research institutions, development of targeted therapies, advancements in biologic drug development, and innovative gene therapies.
The growing emphasis on rare diseases is expected to significantly drive the growth of the Voxzogo market in the future. Rare diseases are conditions that affect a small percentage of the population, typically fewer than 200,000 people in a country. The increased focus on rare diseases is being propelled by advancements in genetic research, the potential for innovative treatments, and heightened awareness of the unmet medical needs of individuals with these conditions. Investments in rare disease research benefit Voxzogo by promoting the development of treatments for conditions such as achondroplasia, expanding its availability and addressing the needs of underserved patient populations. For example, in February 2024, the Government of Canada allocated $20 million to enhance the health outcomes of children living with rare diseases. As a result, the growing attention and funding for rare diseases are fueling the expansion of the Voxzogo market.
The rise of personalized medicine is also expected to contribute to the growth of the Voxzogo market. Personalized medicine refers to treatments tailored to an individual’s genetic profile, lifestyle, and specific health conditions. This approach is gaining traction due to advancements in genomics and precision medicine, which allow for more targeted and effective treatments. Voxzogo aligns with the personalized medicine trend by providing a specific treatment for children with achondroplasia, addressing the unique genetic and biological characteristics of the condition. This tailored approach aims to improve the outcomes and quality of life for affected individuals. In February 2023, the Personalized Medicine Coalition (PMC) reported that 12 new personalized medicines were approved in 2022, accounting for 34% of all new drug approvals. This increase highlights the growing demand for precision treatments based on genetic and biomarker profiles, further driving the growth of the Voxzogo market.
A key trend within the Voxzogo market is the expansion of treatment indications to improve care for individuals with achondroplasia. Expanding these indications aims to provide enhanced growth and bone health benefits not just for the approved age group but also for adolescents and adults with achondroplasia, and potentially for other skeletal dysplasias. In October 2023, BioMarin Pharmaceutical Inc. received FDA approval for Voxzogo (vosoritide) to treat children under five years of age with achondroplasia, expanding its use beyond the previous approval for children aged five and older. Voxzogo, designed to promote linear growth in children with achondroplasia who still have open growth plates, is administered via subcutaneous injections. Clinical evidence suggests that the earlier the treatment starts, the greater the potential benefits for height improvement.
The key company operating in the voxzogo market is BioMarin Pharmaceutical Inc.
North America was the largest region in the voxzogo market in 2024. The regions covered in voxzogo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the voxzogo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Voxzogo (vosoritide) is a biologic drug designed to treat achondroplasia, a condition caused by a genetic mutation in the FGFR3 gene. Voxzogo works by counteracting the effects of FGFR3, promoting endochondral ossification - the process of bone growth at the growth plates - by modulating the activity of C-type natriuretic peptide (CNP), thereby supporting bone growth.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Voxzogo include growth hormone deficiency, Noonan syndrome, achondroplasia, and other conditions. Growth hormone deficiency (GHD) is a medical condition in which the pituitary gland fails to produce or secrete adequate growth hormone (GH), leading to impaired growth. Voxzogo is distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and clinics, and is used by a range of patients, including pediatrics, adults, and the geriatric population.
The voxzogo market consists of sales of injection delivery devices, supportive therapies, genetic testing kits, and growth monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Voxzogo Market Characteristics4. Voxzogo Market Trends And Strategies5. Voxzogo Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Voxzogo Pricing Analysis & Forecasts30. Global Voxzogo Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Voxzogo Market32. Recent Developments In The Voxzogo Market
3. Voxzogo Market Biologic Drug Characteristics
6. Global Voxzogo Growth Analysis And Strategic Analysis Framework
8. Voxzogo Market Segmentation
9. Global Voxzogo Epidemiology Of Clinical Indications
10. Voxzogo Market Regional And Country Analysis
11. Asia-Pacific Voxzogo Market
12. China Voxzogo Market
13. India Voxzogo Market
14. Japan Voxzogo Market
15. Australia Voxzogo Market
16. South Korea Voxzogo Market
17. Western Europe Voxzogo Market
18. UK Voxzogo Market
19. Germany Voxzogo Market
20. France Voxzogo Market
21. Eastern Europe Voxzogo Market
22. North America Voxzogo Market
23. USA Voxzogo Market
24. Canada Voxzogo Market
25. South America Voxzogo Market
26. Middle East Voxzogo Market
27. Africa Voxzogo Market
28. Voxzogo Market Competitive Landscape And Company Profiles
29. Global Voxzogo Market Pipeline Analysis
33. Voxzogo Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Voxzogo Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on voxzogo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for voxzogo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The voxzogo market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Growth Hormone Deficiency; Noonan Syndrome; Achondroplasia; Other Rare Disorders2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Clinics
3) By End User: Pediatrics; Adults; Geriatric Population
Key Companies Profiled: BioMarin Pharmaceutical Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- BioMarin Pharmaceutical Inc.
